Bone Biologics

Value Proposition

Value Proportion

Opportunity

  • Reduced costs
  • Safer treatment – less complications
  • Fewer reoperations

Physicians

  • Improved clinical outcomes will see physicians / health systems drive utilization
  • Established market and reimbursement

Patients

  • Consumers more selective, demand better care
  • Better safety profile
  • Improved fusions and healing

Business Roadmap

Estimated Valuation

~ $40M

2016 - 2019

  • Cell line selection and synthesis
  • Pilot and pivotal animal studies
  • Mice in space study
  • Raise capital to fund first in man trial

~ $150M

2020 - 2022

  • Phase I/II clinical study outside the U.S.
  • Consider exit to strategic company or raise capital to fund Phase III pivotal trial
  • Secure pharma partnership for osteoporosis

~ $300M

2023 - 2024

  • Phase III clinical study in the U.S.
  • Ramp up commercialization plans

~ $600M

2026

  • FDA approval
  • Raise capital for commercialization

Strategic Investors

Hankey Capital

Hankey Capital, LLC|www.hankeycapital.com

Hankey Capital, LLC, a member of the Hankey Group of Companies, is a private equity firm based in Los Angeles, California. The Hankey Group of Companies is one of the largest subprime auto finance lending organizations in the United States and provides a broad array of equity and debt capital solutions to emerging growth companies as well as origination and management of a significant auto and real estate asset-based finance portfolio.

Mtfbiologics

Musculoskeletal Transplant Foundation|www.mtfbiologics.org

Bone Biologics has formed a formal strategic alliance with the Musculo-skeletal Transplant Foundation (MTF) on the collaborative development of osteoinductive products that incorporate MTF’s current product line of natural bone graft substitutes with NELL-1. MTF is the world’s largest allograft supplier and has become one of the major investors in Bone Biologics. It is also the country’s largest full service tissue organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. A non-profit organization, MTF is a consortium of academic medical institutions and organ and tissue recovery organizations across the country. Since its inception in 1987, MTF has recovered tissue from more than 90,000 donors and distributed more than 5 million grafts for transplantation. We anticipate that MTF, with its proven ISO 901 manufacturing and packaging of FDA approved osteogenic carriers, will significantly accelerate the clinical development cycle of NELL-1 related products.

Orthofix

Orthofix|www.orthofix.com

Orthofix International N.V. is a diversified, global medical device company focused on improving patients’ lives by providing superior reconstructive and regenerative orthopedic and spine solutions to physicians worldwide. Headquartered in Lewisville, Texas, the Company has four strategic business units that include BioStim, Biologics, Extremity Fixation and Spine Fixation. Orthofix products are widely distributed via the Company’s sales representatives, distributors and its subsidiaries. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as the Musculoskeletal Transplant Foundation and the Texas Scottish Rite Hospital for Children.

Shares Outstanding

Bone Biologics’ shares were listed on OTCQB market as of March 31, 2016 under the symbol BBLG.

Bone Biologics has a total of 18M diluted shares outstanding

BBLG